



1st August, 2019

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.
Ref.: Scrip Code No. : 540701	Ref. : (i) Symbol – DCAL (ii) Series – EQ

SUB.: Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015: The Company's wholly owned subsidiary, Carbogen Amcis AG's manufacturing site in Hunzenschwil (Neuland), Switzerland has successfully completed a US FDA Pre-Approval Inspection

Dear Sir,

With reference to the captioned subject, we would like to inform that the Company's wholly owned subsidiary, Carbogen Amcis AG's manufacturing site in Neuland, Switzerland, has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection. The inspection was concluded with no Form 483's filed, thus confirming that no critical or major observation was raised during the inspection. The auditor will recommend the approval of API for which the audit was conducted.

The Hunzenschwil facility is one of Carbogen Amcis AG's four sites to offer development and manufacturing facilities for highly potent compounds. It manufactures products according to cGMP standards and is routinely inspected by Swissmedic, the FDA and external customers.

Kindly take this on your record & oblige.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

S. A. Dave
Shrima Dave
Company Secretary



Dishman Carbogen Amcis Limited
(Formerly Carbogen Amcis (I) Ltd)

DISHMAN CORPORATE HOUSE
Iscon-Bopal Road, Ambli, Ahmedabad-380 058. (India)
Phone : +91 (0) 2717 420100 / 420124
E-mail : dcal@dishmangroup.com
Website : www.dishmangroup.com

Regd. Off.: Bhadra-Raj Chambers, Swastik Cross Road,
Navrangpura, Ahmedabad-380 009. (India)
Phone : +91 (0) 79 26443053 / 26445807 / 26560089
Fax : +91 (0) 79 26420198

Government Recognised Export House
CIN No. : L74900GJ2007PLC051338